Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design.
Carberry J, Petrie MC, Lee MMY, Brooksbank K, Campbell RT, Good R, Jhund PS, Kellman P, Lang NN, Mangion K, Mark PB, McConnachie A, McMurray JJV, Meyer B, Orchard V, Shaukat A, Watkins S, Welsh P, Sattar N, Berry C, Docherty KF.
Carberry J, et al. Among authors: berry c.
ESC Heart Fail. 2024 May 7. doi: 10.1002/ehf2.14830. Online ahead of print.
ESC Heart Fail. 2024.
PMID: 38715187